ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives

• Published in: Anticancer research Vol. 40; no. 5; pp. 2457 - 2465
• Main Authors: MASSIMINO, MICHELE, STELLA, STEFANIA, TIRRÒ, ELENA, PENNISI, MARIA STELLA, VITALE, SILVIA RITA, PUMA, ADRIANA, ROMANO, CHIARA, DI GREGORIO, SANDRA, TOMARCHIO, CRISTINA, DI RAIMONDO, FRANCESCO, MANZELLA, LIVIA
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.05.2020
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biomarkers, Tumor; Catalytic activity; Chromosomes; Chronic myeloid leukemia; Comorbidity; Drug dosages; Drug Resistance, Neoplasm - genetics; Effectiveness; Fusion Proteins, bcr-abl - antagonists & inhibitors; Fusion Proteins, bcr-abl - genetics; Gene Expression Regulation, Leukemic - drug effects; Health risks; Hematology; Humans; Imatinib; Kinases; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Life span; Molecular modelling; Molecular Targeted Therapy; Mutation; Myeloid leukemia; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Protein Kinase Inhibitors - therapeutic use; Proteins; Proto-Oncogene Proteins c-abl - antagonists & inhibitors; Proto-Oncogene Proteins c-abl - genetics; Stem cells; Treatment Outcome; Tyrosine; Tyrosine kinase inhibitors; CML; TKI; review; efficacy; resistance; BCR-ABL1

The introduction of tyrosine kinase inhibitors (TKIs) directed against the catalytic activity of the ABL tyrosine kinase has considerably improved the outcome of chronic myeloid leukemia (CML) patients in the chronic phase of the disease. Indeed, these individuals currently show a life-expectancy co...